To evaluate the safety, tolerability, and localization and delivery function of the DDS2 Capsule using gamma scintigraphy in people with active UC in a fasted state. The DDS2 capsule features proprietary localization technology designed to enable precise study drug delivery at the site of disease in the GI tract. Safety and tolerability of the DDS2 capsule has previously been tested in healthy participants. In this study, the DDS2 capsule will deliver a saline solution containing a small amount of non-absorbed radioactive tracer upon entry into the colon of people with ulcerative colitis in a fasted state. Gamma scintigraphy will be used to assess the localization and delivery function of the capsule.

We aim to increase patient knowledge on the impact of IBD on women’s lives.

This Stanford University study aims to identify potential environmental exposure markers that may contribute to the progression of Crohn's disease. 

• We are conducting interviews with adults who have been clinically diagnosed with Ulcerative Colitis (UC) that is currently moderately-to-severely active based on clinician assessment.
• The focus of the interviews will be to gain a better understanding of the participant's experience living with ulcerative colitis, including what symptoms are most important to them and how these symptoms may impact their day-to-day life.

The purpose of this study is to test whether a non-invasive dietary intervention during the last trimester of pregnancy can beneficially shift the microbiome, or the bacterial flora of the body, in patients with Crohn’s disease and in their babies. Crohn's disease, a type of inflammatory bowel disease, is a chronic condition of the gastrointestinal tract that is associated with an imbalance in the gut microbiome. Diet may play a role in the development and treatment of Crohn's disease. Accumulating evidence suggests that maternal health and diet during pregnancy and early life have an impact on the baby’s microbiome composition and immune system development, with long-term health consequences, including establishing risk of developing Crohn's disease and other immune-mediated diseases. By changing the maternal microbiome during pregnancy through diet, we hope to be able to promote healthier immune system development in infants born to mothers with Crohn's disease.

We are conducting interviews with both caregivers of patients with CD and patients with CD between the ages of 5 and 17 years. Through these interviews, we will identify and explore the most important symptoms of CD experienced by children and adolescents. We want to understand how symptoms impact their lives and identify the specific language patients and their caregivers use to describe CD symptoms. With this data, we will create a conceptual model of CD, which will be used to develop a measure for Eli Lilly's clinical trials.

Full Study Title: A 52-Week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active-Controlled (Humira), Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Investigational drug in Participants With Moderately to Severely Active Crohn's Disease [INTREPID]

The primary objectives of this study is to evaluate the efficacy and safety of the investigational drug versus placebo (Stage 1) and versus Humira® (Stage 2) to achieve endoscopic response and clinical remission in participants with moderately to severely active Crohn's Disease (CD) who have failed or are intolerant to conventional therapy (corticosteroids or immunomodulators), or who are biological-treatment naive, have demonstrated a successful response to prior biological treatment, or who have failed or were intolerant to biological treatment.

To investigate the underlying mechanisms of sex differences in statural growth impairment and to develop a predictive model to identify patients at highest risk for developing growth impairment refractory to standard therapeutic approaches